University of Pittsburgh

Unm Rainforest Innovations

Richard L Simmons

Timothy R Billiar

David A Geller

Andreas K Nussler

Camillo D Ricordi

Suzanne T Ildstad

Denis Bragin

Edith Tzeng

Marina V Kameneva

Edwin Nemoto

Christina Kaufman

Sherry M Wren

Methods and compositions for the treatment, amelioration, or prevention of cancer and/or cancer metastasis by delivery of a hemodynamics altering agent such as a drag reducing polymer (DRP).

Hemorheologic approach for reduction/prevention of cancer metastasis formation

A human tissue inducible nitric oxide synthase cDNA clone is disclosed. A process for preparing this cDNA clone coding for human tissue inducible nitric oxide synthase and for expressing the human tissue inducible nitric oxide synthase protein are provided.

Isolated human inducible nitric oxide synthase

The present invention relates to mammalian hematopoietic facilitatory cells (FC). In particular, it relates to the isolation, characterization and uses of the FC. The FC of the present invention can be distinguished from all other known bone marrow cells by their morphology, cell surface phenotype and in vivo function. It has now been established that purified hematopoietic stem cells alone or bone marrow cells depleted of FC do not readily engraft in a recipient. When co-administered with other bone marrow cells, especially the hematopoietic stem cells into a recipient, the FC enhance their engraftment, without apparent adverse biologic activities. In fact, the ability of the FC to enhance the engraftment of bone marrow cells in esablishing lymphohematopoietic chimerism without producing graft versus host disease also induces donor-specific tolerance to permit the permanent acceptance of donor's cells, tissues and organs. Therefore, FC may have a wide range of applications, including, but not limited to, hematopoietic reconstitution by bone marrow transplantation for the treatment of cancers, anemias, autoimmunity, immunodeficiency, viral infections and metabolic disorders as well as facilitation of solid organ, tissue and cellular transplantation.

Hematopoietic facilitatory cells and their uses

The present invention discloses a full-length human hepatocyte iNOS cDNA clone and various gene therapy applications utilizing an iNOS DNA sequence. In preferred embodiments of the disclosed invention, iNOS-directed gene therapy involves specific targeting of a DNA sequence encoding a protein or protein fragment with iNOS biological activity for treating vascular diseases and disorders, antitumor applications and in response to certain microbial infections.

Inducible nitric oxide synthase gene for treatment of disease

cDNA clone for human inducible nitric oxide synthase and process for

Growing community of inventors

Pittsburgh, PA, United States of America

Richard L Simmons